From WisPolitics.com/WisBusiness.com …
— UW-Madison and TAE Life Sciences are taking steps to launch the first of a new type of cancer treatment center.
The two announced today they’ve signed a memorandum of understanding to move forward with the collaboration. As part of the agreement, UW-Madison would install an Alphabeam compact accelerator-based boron neutron capture therapy system developed by TAE, a biotech company that specializes in targeted radiation therapy for cancer care.
The therapy selectively targets cancer cells to minimize the impact on nearby healthy cells. With the Alphabeam technology, patients undergo a short, minimally invasive treatment in one or two sessions.
Dr. Nita Ahuja, vice chancellor for Medical Affairs at UW-Madison, said the effort “signifies our commitment to cancer clinical trials that will give critical access to experimental treatments for difficult-to-treat brain and head and neck cancers.”
“It is an outstanding opportunity to leverage the University of Wisconsin School of Medicine and Public Health’s strengths in areas such as oncology, theranostics, particle therapy, clinical research, drug development and medical physics, aligned with our vision of healthy people and healthy communities,” she added.
Currently, the technology only exists in Japan and China, and will soon be installed in Italy.
See the release.
Top Stories
– RFK Jr.’s next vaccine target
– Senators Press Deloitte, Other Contractors on Errors in Medicaid Eligibility Systems
– Cops on Ketamine? Largely Unregulated Mental Health Treatment Faces Hurdles
Press Releases
